These positions were eliminated after Panacos sold bevirimat, and the company has refocused its efforts on its early stage programs. Dr McCallister has served in this capacity since October 2006, and Dr Richards joined the company in February 2006.
Alan Dunton, president and CEO of Panacos, said: “I have tremendous respect for Scott and John and their devotion to Panacos and bevirimat. As a practicing clinician on the front lines, Scott knows better than most the need to bring new products to the market that improve the lives of people living with HIV.
“John and his team solved one of the major issues for bevirimat, the ability to create a viable tablet formulation, which was a huge advance in the development of this critical product for HIV. We know Scott and John will be invaluable to their colleagues at their next endeavors.”